Surgical Anatomy of the Distal Portion of the Phrenic Nerve (DANP)

October 22, 2021 updated by: Assistance Publique - Hôpitaux de Paris
Prolonged mechanical ventilation has been shown to induce diaphragm dysfunction. Temporary diaphragm pacing is an interesting lead to halt or slow diaphragm dysfunction. A detailed description of the distal portion of the phrenic nerve would be the start for developing a new surgical approach for diaphragm pacing. Its in that perspective that we are launching a clinical observational study of the distal portion of the phrenic nerve in patients who undergo minimally invasive thoracic surgey. We hypothetize that the density of the fatty tissue surrounding the distal portion of the phrenic nerve might influence efficiency of the electrode during diaphragm pacing. The objective of this study is to find a correlation between the amount of fatty tissue around the nerve and the body mass index of individuals.

Study Overview

Status

Completed

Conditions

Detailed Description

Implanted phrenic nerve stimulation is a validated technique to produce lung ventilation when the neural drive to breathe is abolished (e.g. congenital central alveolar ventilation during sleep, or during wakefulness in severe forms of the disease) or defective (e.g. periodic breathing due to chronic heart failure), or when it cannot reach the phrenic spinal motoneurons (e.g. high cervical spinal cord lesions). Several implantation techniques have been described. They include the surgical implantation of contact electrodes in intimate exposure with the trunk of the nerve, the laparoscopic implantation of hook electrodes within the diaphragm in the vicinity of the phrenic nerve endings (ref), and transvenous approaches that can be permanent (pacemaker like device) or temporary (central venous catheter-borne electrodes). The surgical implantation of electrodes in contact with the phrenic nerve ("periphrenic electrodes") is the better established of these techniques, having been described in the 1970s and continuously used since. Periphrenic electrodes have been implanted at the bottom of the cervical path of the nerve. This cervical approach is quick and easy to implement, but the results can be compromised by system damages resulting from neck movements and by the fact that the phrenic nerve is often anatomically incomplete at this level (namely above the junction with the accessory phrenic nerve). For these reasons, periphrenic electrodes are typically implanted within the thorax, at the level of the vena cava on the right and of the pulmonary hilum on the left. These locations are readily accessible by use of video-assisted thoracoscopic surgery or thoracotomy. Careful dissection of the phrenic nerve is necessary to separate it from the underlying anatomical plane and create the necessary access to position the electrodes. The possibility to position periphrenic electrodes over a segment of the phrenic nerve where it would be fully constituted and to do so without the need for nerve dissection would render intrathoracic phrenic nerve stimulation easier and safer to implement. It would also open the possibility of temporary implantation. From the anatomical description of the terminal branching of the phrenic nerve toward different portions of the diaphragm , we hypothesized that such "free" segment would exist between the point where the phrenic nerve pathway leaves the anterolateral angle of the pericardial base in direction of the diaphragm and the point where the phrenic nerve branches before entering the diaphragm muscle mass. This study was therefore designed to determine whether or not a free phrenic segment exists between the cardiophrenic angle and the diaphragm, to describe the anatomical characteristics of this segment, and to compare the nature, number and size of its constituting fibers with the corresponding characteristics as identified at the usual site of implantation of intrathoracic periphrenic electrodes. To this aim, we first performed a human cadaver study. This study allowed us to describe a fatty tissue surrounding the phrenic nerve which density vary from one patient to another, and from one side to the other. During routine surgical interventions by minimally invasive approach, we want to complete our observation by searching for a correlation between patients body mass index (BMI) and the density of fatty tissue surrounding the phrenic nerve.

The patients, depending on their BMI will be divided in three categories: - Category 1: 18,5 kg/m2 < BMI < 24,9 kg/m2 / - Category 2: 25 kg/m2 < BMI < 29,9 kg/m2 / - Category 3: 30,0 kg/m2 < BMI < 34,9 kg/m2 Fifteen patients will be included in each category. A fifteen seconds recording of each phrenic nerve during minimally invasive surgery will be reviewed by 2 independent observers in order to classify the phrenic nerve in three categories: - type 1: pericadiophrenic bundle is free of any relevant surrounding fatty tissue / - Type 2: pericardiophre-nic bundle is surrounded by one fringe of fatty tissue / - Type 3: pericardiophrenic bundle is surrounded by multiple fringes of fatty tissue

Study Type

Observational

Enrollment (Actual)

54

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75020
        • Tenon Hospital, Service : Chirurgie Vasculaire et Thoracique

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study population will be patients who consult for a benign or malignant pulmonary lesion. Resection of the lesion would have to be done by a minimally invasive approach (video-assisted thoracoscopic surgery or robotic-assisted thoracoscopic surgery).

Description

Inclusion Criteria:

  • patients older than 18 years-old and not under a protection measure
  • patients undergoing lung resection for a malignant or benign lesion
  • surgical approach by minimally invasive technique (video-assisted thoracoscopic surgery or robotic-assisted thoracoscopic surgery)

Exclusion Criteria:

  • surgical approach by thoracotomy
  • intense pleural adhesions between the lung parenchyma and the mediastinal pleura.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Minimally invasive surgery for a benign or malignant pulmonary lesion.

The patients will be divided in three categories depending on the Body Mass Index:

  • Category 1: 18,5 kg/m2 < BMI < 24,9 kg/m2 -Category 2: 25 kg/m2 < BMI < 29,9 kg/m2 /
  • Category 3: 30,0 kg/m2 < BMI < 34,9 kg/m2

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
correlation between body mass index and fatty tissue surrounding phrenic nerve
Time Frame: Day 0
During the initial phase of the surgical intervention, the surgeons would explore the thoracic cavity for potential contra-indications of any lung resection. While doing so, they would identify the phrenic nerve in order to prevent any lesions. During that particular moment, the recording option on the camera would be activated to register exploration of the distal portion of the phrenic nerve before it ends in the diaphragm. Two independent observers would review this video and classify the phrenic nerve depending on the amount of fatty tissue surrounding it.
Day 0

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Inter-Observer Variability
Time Frame: Up to 3 weeks
after classification of fatty tissue around the phrenic nerve by the two observers, inter observer variability will be assessed by using Kappa coefficient from Cohen.
Up to 3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jalal Assouad, PUPH, Assistance Publique - Hôpitaux de Paris

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 23, 2021

Primary Completion (Actual)

April 30, 2021

Study Completion (Actual)

April 30, 2021

Study Registration Dates

First Submitted

January 15, 2021

First Submitted That Met QC Criteria

January 15, 2021

First Posted (Actual)

January 20, 2021

Study Record Updates

Last Update Posted (Actual)

October 25, 2021

Last Update Submitted That Met QC Criteria

October 22, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • APHP201072

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diaphragm Disease

3
Subscribe